55 results about "Yellow fever" patented technology

The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV in human patients or other animal hosts. The compounds are certain 6-substituted purine monophosphates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1, HIV-2, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV.

The present invention is directed to compounds, compositions and methods for treating or preventing viral infections using nucleoside analog monophosphate prodrugs. More specifically, HCV, Norovirus, Saporovirus, Dengue virus, Chikungunya virus and Yellow fever in human patients or other animal hosts. The compounds are certain 2,6-diamino 2-C-methyl purine nucleoside monophosphate prodrugs and modified prodrug analogs, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HCV, Norovirus, Saporovirus, Dengue virus, Chikungunya virus and Yellow fever. This invention teaches how to modify the metabolic pathway of 2,6-diamino 2′-C-methyl purine and deliver nucleotide triphosphate(s) to polymerases at heretofore unobtainable therapeutically-relevant concentrations.

The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV in human patients or other animal hosts. The compounds are certain 6-substituted purine monophosphates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1, HIV-2, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV.

Compounds having unique antiviral properties are prepared from medicinal mushroom mycelium, extracts and derivatives. The compositions are derived from Fomitopsis, Piptoporus, Ganoderma and blends of medicinal mushroom species and are useful in preventing and treating viruses including Orthopox viruses, influenza, avian influenza, Venezuelan Equine Encephalitis, yellow fever, West Nile, Dengue, New World and Old World arenaviruses, hantavirus, Rift Valley fever, sandfly fever, hantavirus, SARS, Rhinovirus and other viruses.

The invention discloses a fluorescence quantitative polymerase chain reaction (PCR) new method for detecting multiple viruses of yellow fever, dengue fever and epidemicencephalitis B and multiple virus detection PCR system consisting of primers, probes, a Premix Ex Taq reaction solution and a sterilized Tris buffer. With good singularity and high sensitivity, three pairs of primers and probes are very suitable for simultaneously detecting viruses of yellow fever, dengue fever and epidemicencephalitis B. And there is no cross reaction between the primers and probes and several other entomophily hemorrhagic fever viruses, such as Marburg virus and Rift Valley fever virus.

The present invention is directed to compounds, compositions and methods for treating or preventing viral infections using nucleoside analog monophosphate prodrugs. More specifically, HCV, Norovirus, Saporovirus, Dengue virus, Chikungunya virus and Yellow fever in human patients or other animal hosts. The compounds are certain 2,6-diamino 2-C-methyl purine nucleoside monophosphate prodrugs and modified prodrug analogs, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HCV, Norovirus, Saporovirus, Dengue virus, Chikungunya virus and Yellow fever. This invention teaches how to modify the metabolic pathway of 2,6-diamino 2'-C-methyl purine and deliver nucleotide triphosphate(s) to polymerases at heretofore unobtainable therapeutically-relevant concentrations.

The invention belongs to the field of biological products, and particularly relates to a process for producing a yellow fever attenuated live vaccine by using SPF chicken embryo cells. According to the process, a 17D attenuated vaccine strain provided by WHO is used, and is subjected to passage adaptation by using chicken embryo cells to prepare virulent seeds, chicken embryo cells cultured by cell factory are inoculated as matrix cells for virus culture, culture is performed, the virus solution is collected, sterilization is performed, a gelatin-free protection agent is added, and freeze drying is performed to prepare the finished product vaccine. According to the present invention, the efficacy index of vaccine meets the WHO standard, other quality test standards meet the requirement ofthe Pharmacopoeia of the People's Republic of China Volume 3 (2015 edition), and the product is used for preventing yellow fever infection.

The invention discloses a cyclocompound of tetrahydropyrrole and dihydroimidazolone as well as preparation and pharmaceutical application thereof. The cyclocompound is a compound shown in a formula (I), an isomer or pharmaceutically acceptable salt thereof. The compound, isomer or pharmaceutically acceptable salt thereof can be applied to preparation of medicines used for preventing or treating related diseases (such as dengue fever, dengue hemorrhagic fever, dengue shock syndrome, Zika, Chikungunya, Japanese encephalitis, yellow fever, hepatitis C and West Nile disease) caused by a dengue fever virus and related viruses. (The formula (I) is described in the specification).

Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel semicarbazides, sulfonyl carbazides, ureas and related compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to Arenaviridae (Junin, Machupo, Guanavito, Sabia and Lassa), Filoviridae (ebola and Marburg viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).

Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, Pichinde, and LCMV), Filoviridae (Ebola and Marburg viruses), Flaviviridae (yellow fever, Omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever and Crimean-Congo hemorrhagic fever).

The invention discloses use of a dipeptide analogue, and particularly relates to use of compounds in formulas (I) and (II), a stereisomer or a pharmaceutically acceptable salt thereof in pharmaceutical aspects. The compounds shown in the formulas (I) and (II) can be utilized as drugs for treating and preventing a disease caused by a dengue fever virus, and simultaneously can become the drugs for treating and preventing the disease caused by other flaviviruses, such as a yellow fever disease, hepatitis c, Japanese encephalitis, forest encephalitis, a disease caused by west nile virus infection, or aids caused by a human immunodeficiency virus (HIV) and the like.

The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya and West Nile virus), RSV and influenza infection and cancer in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.

The invention discloses an insect repellent and insecticide composition. The insect repellent and insecticide composition comprises (a) lemon grass oil (citronella oil), (b) p-menthyl-3, 8-diol, (c) vanillin and (d) a transport medium, wherein the mass ratio of p-menthyl-3, 8-diol to lemon grass oil (citronella oil) is 10 to 2:1. The insect repellent and insecticide composition reduces the limitation of the existing product based on the known natural ingredients. Through the synergism of two or more insect repellent materials, the unique formula can produce additional benefits and superior effects. The research results show that the novel composition can effectively repel mosquitoes and has a strong repellent effect. The formula containing lemongrass oil (citronella oil) and p-menthyl-3, 8-diol can effectively resist mosquito-borne malarial mosquito and Aedes aegypti transmitting dengue fever and yellow fever.

The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya and West Nile virus), RSV, HEV, and influenza infection and cancer in human subjects or other animal hosts.

The invention discloses cyclic formyl and cyclic ketone compounds as well as a preparation method and a pharmaceutical application thereof. The compound shown in (I) has a good function of inhibitinginfection and replication of Zika viruses and dengue viruses; the compounds can be used as medicines for treating and preventing diseases caused by Zika virus and dengue virus. The compound can be used as a medicine for treating and preventing diseases caused by other flaviviruses, such as yellow fever, west nile virus infection, encephalitis B caused by encephalitis B virus infection, chikungunyavirus infection, hepatitis C, forest encephalitis, AIDS caused by HIV, diseases caused by hand-foot-and-mouth virus infection and the like. The compound can be used for treating diseases caused by bacterial infection, including ulcerative colitis and Crohn's disease of inflammatory bowel disease, diseases caused by escherichia coli, diseases caused by staphylococcus aureus and the like, and diseases caused by acinetobacter baumannii.

The present invention relates to an attenuated, recombinant viral vaccine against yellow fever which expresses heterologous sequences of a lentivirus and is used as an immunisation agent to induce an immune response to lentivirus.